
By Dr. Anupama Hariharan | Associate Director, Biotechnology Contract Research Organization
Success in cell and gene therapies is considered a breakthrough in science, but it is equally a product of breakthrough operations. Unlike conventional investigational medicinal products, cell and gene therapies are living, time sensitive, patient specific, and require operationally sound risk management strategies.
They demand precise coordination across patient identification, tissue collection, chain of identity, manufacturing slots, cryogenic logistics, product release, site readiness, administration, and long term follow up. This article explores why cell and gene therapy trials need a new execution model comprising an integrated system of clinical operations, manufacturing, logistics, quality, and patient support rather than separate workstreams.
Introduction: Traditional Clinical Trials vs Modern Cell and Gene Therapies
Traditional clinical trial operations were built around medicines that could be manufactured, packaged, shipped, stored, dispensed, and administered with a reasonable degree of separation between the supply chain and the patient journey. Cell and gene therapies disrupt that model.
This creates a new operational reality. A missed collection window, a temperature excursion, a labelling error, a delayed manufacturing slot, or an unprepared investigational site can compromise not only trial efficiency but also patient safety and product viability. For living medicines, clinical operations is no longer merely an execution function. It becomes a central determinant of whether the therapy can be delivered at all.
Challenges with Conventional Trial Models
Conventional trial models can be inadequate for cell and gene therapies because they assume investigational product management can be handled through standard inventory, storage, accountability, and dosing processes.
Living medicines require a more dynamic execution model. They often involve individualized batches, limited stability windows, complex handling, specialized administration, and multidisciplinary site teams. Operational plans must therefore synchronize patient readiness with manufacturing capacity, logistics performance, site capability, and release timelines in real time.
Evolving global regulatory expectations further reinforce the need for early operational design that protects product quality, patient safety, and data integrity throughout the therapy journey.
Operational Challenges of Living Medicines
1. Chain of Identity and Chain of Custody Are Safety Critical
In autologous therapies, the cells collected from one patient must be returned to the same patient after processing or genetic modification. Appropriate documentation confirms that the biological material remains correctly linked to the individual patient.
Challenges can arise around who handled the material, where it was located, and under what conditions it was maintained. A failure in this process is not a routine deviation. It can become a serious patient safety event.
2. Manufacturing as an Integral Part of Clinical Scheduling
Cell and gene therapy trials frequently depend on manufacturing slots, release testing, batch specific documentation, and narrow administration windows.
Clinical teams must coordinate premedication, patient conditioning, hospital admission, infusion timing, and rescue medication readiness around manufacturing milestones. A delay at one node can cascade across the entire treatment pathway.
3. Specialized Logistics Oversight
Many cell based products require cryopreservation, ultra low temperature shipment, continuous monitoring, validated packaging, and contingency planning.
Product viability depends on strict handling conditions from collection through manufacturing, shipment, storage, thawing, and administration. Clinical operations teams must therefore understand logistics as an extension of protocol execution rather than simply vendor based logistics handling.
4. Site Readiness
Site activation for living medicines requires more than essential document collection and investigator training.
Sites may need validated storage capacity, trained pharmacy or cell processing teams, emergency response pathways, intensive monitoring procedures, multidisciplinary coordination, and rehearsed product receipt and administration workflows.
The site must be operationally ready in practice, not simply activated on paper.
5. Patient Experience
Patients may require genetic testing, leukapheresis, bridging therapy, lymphodepletion, travel support, caregiver coordination, inpatient monitoring, long term safety follow up, and rapid adverse event management.
In rare diseases and oncology, patients may already be clinically vulnerable. Operational excellence must therefore include navigation support, scheduling discipline, clear communication, and contingency planning for clinical deterioration.
Next Generation Execution Model for Cell and Gene Therapy Trials
The next generation execution model should be built around an integrated approach. Instead of managing clinical operations, manufacturing, logistics, regulatory, data management, and patient support as parallel functions, a unified operating model should be created with shared timelines, distinct risk ownership, and real time escalation pathways.
Programs should establish an end to end patient to product map. The map should begin with screening and consent and continue through collection, manufacturing, release, shipment, administration, careful monitoring, and long term follow up. Every handoff should have an accountable owner, a defined time window, a required documentation step, and a predefined contingency plan.
Site selection should prioritize capability over enrollment potential. For living medicines, a high enrolling site without appropriate infrastructure can create more risk than value. Site feasibility should assess operational maturity, staffing stability, specialty service integration, prior advanced therapy experience, storage and handling capacity, emergency preparedness, and willingness to participate in simulation based readiness checks.
Training should shift from presentation based learning to workflow rehearsal. Teams should conduct mock runs for apheresis, product receipt, temperature excursion response, patient admission, thawing, administration, and adverse event escalation. These rehearsals can reveal process gaps that may remain invisible during slide based training.
Digital oversight and tracking should become integral to execution. Paper logs and disconnected spreadsheets are poorly suited to patient specific therapies. Digital platforms can support chain of identity, chain of custody, scheduling, shipment monitoring, release status, deviation management, and stakeholder communication. However, technology should support, not substitute for, well defined processes and trained decision makers.
Risk management should be dynamic and scenario based. Risk scenarios should consider manufacturing failure, shipping delays, patient clinical deterioration, product temperature excursions, site staffing gaps, and delayed release testing. Each scenario should have an escalation owner, decision criteria, communication template, and documented recovery pathway.
Risk mitigation should not be viewed as the only risk management strategy. Other approaches, including risk avoidance and risk transference, should also be considered where appropriate.
Clinical Operations Leader and the Pivot Point
This role requires more than study management. It requires an understanding of manufacturing constraints, site workflows, regulatory expectations, patient vulnerability, and data integrity.
In cell and gene therapy development, the clinical operations leader becomes an integrator of science, logistics, quality, patient care, and risk management, while translating complex processes into practical trial conduct.
The most successful programs will likely be those in which clinical operations is involved early in protocol design. Operational feasibility should shape visit schedules, eligibility criteria, collection requirements, safety monitoring plans, site burden, country selection, and patient travel expectations.
Requirement for Scalable Networks
As pipelines expand and therapies move into broader indications, the field will need scalable networks that can maintain quality while improving access.
This does not mean lowering standards. It means standardizing readiness, training, documentation, logistics, and escalation pathways so that more qualified centres can participate safely.
Expansion into community or regional care settings will require careful qualification. Some components may be decentralized or distributed, but critical steps such as collection, product receipt, administration, and emergency management must remain tightly controlled.
The future model may involve hub and spoke systems, centralized manufacturing support, regional collection centres, mobile patient navigation, and digital oversight across the therapy journey.
Operational Excellence: An Ethical Obligation
For patients with serious, progressive, or rare diseases, cell and gene therapy trials may represent a meaningful opportunity when available treatment options are limited.
Operational success is therefore imperative and can be ethically consequential. Delays, avoidable screen failures, preventable product loss, unclear communication, or poorly coordinated follow up can impose significant burdens on already vulnerable patients and families.
Evolving high standards in advanced therapy development should therefore include operational standards. Sponsors, CROs, sites, manufacturers, logistics providers, and regulators all have a role in building systems that protect patient trust as effectively as they protect product integrity.
Conclusion: The Future of Living Medicines Depends on Living Operations
Cell and gene therapies are prompting the clinical research community to rethink execution beyond traditional practices. A coordinated operating model is needed to preserve identity, viability, quality, safety, and patient access across a complex journey.
The next era of clinical operations must move from task management to therapy orchestration.
For living medicines, excellence is achieved when every function understands that the investigational product, the patient journey, and the clinical trial process are inseparable.
In that sense, the new execution model for cell and gene therapy trials is not simply an operational upgrade. It is a prerequisite for transforming innovation into reliable, scalable, and ethical standards of care.







